

Neuland Laboratories Limited  
Sanali Info Park, 'A' Block,  
Ground Floor, 8-2-120/113  
Road No. 2, Banjara Hills  
Hyderabad - 500 034.  
Telangana, India.

Tel: 040 30211600 / 23551081  
Fax: 040 30211602  
Email: neuland@neulandlabs.com  
www.neulandlabs.com

February 3, 2018

To  
B S E Limited  
Phiroze Jeejeebhoy Towers,  
25<sup>th</sup> Floor, Dalal Street,  
Mumbai - 400 001

To  
The National Stock Exchange of India Ltd  
Exchange Plaza,  
Bandra Kurla Complex  
Bandra (E)  
Mumbai - 400 001

Scrip Code: 524558

Scrip Code: NEULANDLAB  
Series: EQ

Dear Sirs,

**Sub: Compliance with Regulation 47 (1) (b) of the SEBI Listing Regulations, 2015**

Please find attached herewith copies of the newspaper publication of Un-audited financial results for the quarter ended December 31, 2017, published in Financial Express and Andhra Prabha on February 3, 2018, for your reference.

Thanking you,

Yours faithfully,  
For Neuland Laboratories Limited



**Sarada Bhamidipati**  
Company Secretary

Encl : as above



NEULAND LABORATORIES LIMITED					
(CIN : L85195TG1984PLC004393)					
Regd. office: Sanali Info park, 'A' Block, Ground floor					
8-2-120/113, Road No.2, Banjara Hills, Hyderabad-500034					
UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2017					
(Amount in lakhs of ₹, unless otherwise stated)					
Sl. No.	Particulars	Quarter Ended		Nine Months Ended	
		31.12.2017	30.09.2017	31.12.2016	31.12.2016
	(e) Finance costs	481.22	523.19	506.14	1,480.98
	(f) Depreciation and amortisation expense	553.51	538.34	481.85	1,602.07
	(g) Manufacturing expenses	1,647.99	1,914.71	1,437.74	5,500.65
	(h) Other expenses	1,568.83	1,736.38	2,052.64	5,038.88
	Total Expenses	11,640.01	12,210.84	12,927.27	35,521.97
3	Profit before tax (1-2)	88.37	408.28	561.61	839.50
	Tax expense				3,504.68
	(a) Current tax	(42.89)	194.83	329.05	1,318.93
	(b) Deferred tax benefit	10.50	(45.99)	(130.69)	(107.17)
5	Profit for the period (3-4)	120.76	259.44	363.25	609.98
6	Other comprehensive income (net of taxes)				2,337.23
	(a) Items that will not be reclassified to profit or loss				
	(i) Re-measurement losses on defined benefit plans	(5.55)	(5.56)	(5.56)	(16.67)
	(b) Items that will be reclassified to profit or loss				
	Total comprehensive income	115.21	253.88	357.69	593.31
7	Paid-up Equity Share Capital (Face value of ₹10 per share)	895.49	895.49	895.49	895.49
8	Earnings Per Share (of ₹10 each) (In absolute ₹ terms)				
	(a) Basic (refer note 6)	1.36	2.92	4.09	6.87
	(b) Diluted (refer note 6)	1.36	2.92	4.09	6.87

	(e) Finance costs	481.22	523.19	506.14	1,480.98	1,691.30
	(f) Depreciation and amortisation expense	553.51	538.34	481.85	1,602.07	1,372.34
	(g) Manufacturing expenses	1,647.99	1,914.71	1,437.74	5,500.65	4,484.67
	(h) Other expenses	1,568.83	1,736.38	2,052.64	5,038.88	6,184.00
	Total Expenses	11,640.01	12,210.84	12,927.27	35,521.97	40,380.23
3	Profit before tax (1-2)	88.37	408.28	561.61	839.50	3,504.68
	Tax expense					
	(a) Current tax	(42.89)	194.83	329.05	336.69	1,318.93
	(b) Deferred tax benefit	10.50	(45.99)	(130.69)	(107.17)	(151.48)
5	Profit for the period (3-4)	120.76	259.44	363.25	609.98	2,337.23
6	Other comprehensive income (net of taxes)					
	(a) Items that will not be reclassified to profit or loss					
	(i) Re-measurement losses on defined benefit plans	(5.55)	(5.56)	(5.56)	(16.67)	(16.67)
	(b) Items that will be reclassified to profit or loss					
	Total comprehensive income	115.21	253.88	357.69	593.31	2,320.56
7	Paid-up Equity Share Capital (Face value of ₹10 per share)	895.49	895.49	895.49	895.49	895.49
8	Earnings Per Share (of ₹10 each) (In absolute ₹ terms)					
	(a) Basic (refer note 6)	1.36	2.92	4.09	6.87	26.31
	(b) Diluted (refer note 6)	1.36	2.92	4.09	6.87	26.31

See accompanying notes to the financial results

#### NOTES:

1 The unaudited standalone financial results for the quarter ended 31 December 2017 and year to date result for the period 1 April 2017 to 31 December 2017, have been reviewed by the Audit Committee in their meeting held on 1 February 2018, approved and taken on record of the Board by the Board of Directors at their meeting held on 2 February 2018. These results have been subjected to a "Limited Review" by the Statutory Auditors of the Company.

2 The Company adopted Indian Accounting Standards ("Ind AS") from 1 April 2017 and accordingly these results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34, Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting pronouncements generally accepted in India. Financial results for corresponding period presented have been prepared in accordance with the recognition and measurement principles of Ind AS 34.

3 The operations of the Company are predominantly related to the manufacture of Active Pharmaceutical Ingredients (API). As such there is only one primary reportable segment as per Ind AS 108 "Operating Segments".

4 Reconciliation between financial results as previously reported under Previous GAAP and Ind AS for the quarter and nine months ended 31 December 2016:

Amount (₹ in lakhs)		
Particulars	Quarter Ended 31.12.2016	Nine Months Ended 31.12.2016
Net profit under previous GAAP	381.25	2,391.25
Interest on borrowings from related parties	(21.07)	(63.22)
Recognition of rental income at fair value	3.48	10.43
Remeasurement of employee benefits	(4.48)	(13.44)
Others	(5.46)	(16.38)
Deferred tax benefit	9.53	28.59
Total net profit for the period under Ind AS	363.25	2,337.23
Other comprehensive income	(5.56)	(16.67)
Total comprehensive income	357.69	2,320.56

5 In November 2016, the Board of Directors of the Company approved a Scheme for amalgamation of its parent company Neuland Health Sciences Private Limited (NHSPL) and a fellow subsidiary Neuland Pharma Research Private Limited (NPRPL) with the Company. The Scheme of amalgamation has been drawn in accordance with the provisions of the Companies Act, 2013 pursuant to which and subject to requisite regulatory approvals, the entire business undertakings of NHSPL and NPRPL will be transferred to the Company with effect from 1 April 2016. Further, pursuant to the terms of the scheme, the Company shall cancel 4,590,608 equity shares presently held by its parent company NHSPL, and it shall allot the fresh equity share capital to the shareholders of NHSPL and NPRPL in the following ratio duly determined by independent valuation experts:

- 552 equity shares of the Company of ₹10 each, fully paid-up for every 1,000 equity shares of NHSPL of ₹10 each, fully paid up and;

- 410 equity shares of the Company of ₹10 each, fully paid-up for 100 equity shares of NPRPL of ₹10 each, fully paid up.

As at the date of approval of this statement, the Scheme of amalgamation has been duly approved by the Securities and Exchange Board of India, shareholders, creditors of the Company and is subject to and pending for the requisite approvals from the National Company Law Tribunal. Although the scheme, on obtaining the requisite approvals, shall be effective from 1 April 2016, however, pending final approval from National Company Law Tribunal and to comply with the Listing (Obligations and Disclosures) Regulations, 2015, the accompanying statement for the quarter and nine months ended 31 December 2017 have been prepared without giving any effect of the proposed amalgamation.

6 EPS for the quarters and nine months period is not annualized.

7 Revenue from operations for the quarter and nine months ended 31 December 2017 is not comparable with revenue from operations of the corresponding quarter of the previous year and nine months ended 31 December 2016 as these periods include amount of excise duty which is not included for the quarter ended 31 December 2017 after implementation of Goods and Service Tax.

By Order of the Board  
For Neuland Laboratories Limited

NEULAND LABORATORIES LIMITED					
(CIN : L85195TG1984PLC004393)					
Regd. office: Sanali Info park, 'A' Block, Ground floor					
8-2-120/113, Road No.2, Banjara Hills, Hyderabad-500034					
UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2017					
(Amount in lakhs of ₹, unless otherwise stated)					
Sl. No.	Particulars	Quarter Ended		Nine Months Ended	
		31.12.2017	30.09.2017	31.12.2016	31.12.2016
	(e) Finance costs	481.22	523.19	506.14	1,480.98
	(f) Depreciation and amortisation expense	553.51	538.34	481.85	1,602.07
	(g) Manufacturing expenses	1,647.99	1,914.71	1,437.74	5,500.65
	(h) Other expenses	1,568.83	1,736.38	2,052.64	5,038.88
	Total Expenses	11,640.01	12,210.84	12,927.27	35,521.97
3	Profit before tax (1-2)	88.37	408.28	561.61	839.50
	Tax expense				3,504.68
	(a) Current tax	(42.89)	194.83	329.05	1,318.93
	(b) Deferred tax benefit	10.50	(45.99)	(130.69)	(107.17)
5	Profit for the period (3-4)	120.76	259.44	363.25	609.98
6	Other comprehensive income (net of taxes)				2,337.23
	(a) Items that will not be reclassified to profit or loss				
	(i) Re-measurement losses on defined benefit plans	(5.55)	(5.56)	(5.56)	(16.67)
	(b) Items that will be reclassified to profit or loss				
	Total comprehensive income	115.21	253.88	357.69	593.31
7	Paid-up Equity Share Capital (Face value of ₹10 per share)	895.49	895.49	895.49	895.49
8	Earnings Per Share (of ₹10 each) (In absolute ₹ terms)				
	(a) Basic (refer note 6)	1.36	2.92	4.09	6.87
	(b) Diluted (refer note 6)	1.36	2.92	4.09	6.87

	(e) Finance costs	481.22	523.19	506.14	1,480.98	4,863.26
	(f) Depreciation and amortisation expense	553.51	538.34	481.85	1,602.07	1,372.34
	(g) Manufacturing expenses	1,647.99	1,914.71	1,437.74	5,500.65	4,484.67
	(h) Other expenses	1,568.83	1,736.38	2,052.64	5,038.88	6,184.00
	Total Expenses	11,640.01	12,210.84	12,927.27	35,521.97	40,380.23
3	Profit before tax (1-2)	88.37	408.28	561.61	839.50	3,504.68
	Tax expense					
	(a) Current tax	(42.89)	194.83	329.05	336.69	1,318.93
	(b) Deferred tax benefit	10.50	(45.99)	(130.69)	(107.17)	(151.48)
5	Profit for the period (3-4)	120.76	259.44	363.25	609.98	2,337.23
6	Other comprehensive income (net of taxes)					
	(a) Items that will not be reclassified to profit or loss					
	(i) Re-measurement losses on defined benefit plans	(5.55)	(5.56)	(5.56)	(16.67)	(16.67)
	(b) Items that will be reclassified to profit or loss					
	Total comprehensive income	115.21	253.88	357.69	593.31	2,320.56
7	Paid-up Equity Share Capital (Face value of ₹10 per share)	895.49	895.49	895.49	895.49	895.49
8	Earnings Per Share (of ₹10 each) (In absolute ₹ terms)					
	(a) Basic (refer note 6)	1.36	2.92	4.09	6.87	26.31
	(b) Diluted (refer note 6)	1.36	2.92	4.09	6.87	26.31

See accompanying notes to the financial results

#### NOTES:

1 The unaudited standalone financial results for the quarter ended 31 December 2017 and year to date result for the period 1 April 2017 to 31 December 2017, have been reviewed by the Audit Committee in their meeting held on 1 February 2018, approved and taken on record of the Board by the Board of Directors at their meeting held on 2 February 2018. These results have been subjected to a "Limited Review" by the Statutory Auditors of the Company.

2 The Company adopted Indian Accounting Standards ("Ind AS") from 1 April 2017 and accordingly these results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34, Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting pronouncements generally accepted in India. Financial results for corresponding period presented have been prepared in accordance with the recognition and measurement principles of Ind AS 34.

3 The operations of the Company are predominantly related to the manufacture of Active Pharmaceutical Ingredients (API). As such there is only one primary reportable segment as per Ind AS 108 "Operating Segments".

4 Reconciliation between financial results as previously reported under Previous GAAP and Ind AS for the quarter and nine months ended 31 December 2016:

Amount (₹ in lakhs)		
Particulars	Quarter Ended 31.12.2016	Nine Months Ended 31.12.2016
Net profit under previous GAAP	381.25	2,391.25
Interest on borrowings from related parties	(21.07)	(63.22)
Recognition of rental income at fair value	3.48	10.43
Remeasurement of employee benefits	(4.48)	(13.44)
Others	(5.46)	(16.38)
Deferred tax benefit	9.53	28.59
Total net profit for the period under Ind AS	363.25	2,337.23
Other comprehensive income	(5.56)	(16.67)
Total comprehensive income	357.69	2,320.56

5 In November 2016, the Board of Directors of the Company approved a Scheme for amalgamation of its parent company Neuland Health Sciences Private Limited (NHSPL) and a fellow subsidiary Neuland Pharma Research Private Limited (NPRPL) with the Company. The Scheme of amalgamation has been drawn in accordance with the provisions of the Companies Act, 2013 pursuant to which and subject to requisite regulatory approvals, the entire business undertakings of NHSPL and NPRPL will be transferred to the Company with effect from 1 April 2016. Further, pursuant to the terms of the scheme, the Company shall cancel 4,590,608 equity shares presently held by its parent company NHSPL, and it shall allot the fresh equity share capital to the shareholders of NHSPL and NPRPL in the following ratio duly determined by independent valuation experts:

- 552 equity shares of the Company of ₹10 each, fully paid-up for every 1,000 equity shares of NHSPL of ₹10 each, fully paid up and;

- 410 equity shares of the Company of ₹10 each, fully paid-up for 100 equity shares of NPRPL of ₹10 each, fully paid up.

As at the date of approval of this statement, the Scheme of amalgamation has been duly approved by the Securities and Exchange Board of India, shareholders, creditors of the Company and is subject to and pending for the requisite approvals from the National Company Law Tribunal. Although the scheme, on obtaining the requisite approvals, shall be effective from 1 April 2016, however, pending final approval from National Company Law Tribunal and to comply with the Listing (Obligations and Disclosures) Regulations, 2015, the accompanying statement for the quarter and nine months ended 31 December 2017 have been prepared without giving any effect of the proposed amalgamation.

6 EPS for the quarters and nine months period is not annualized.

7 Revenue from operations for the quarter and nine months ended 31 December 2017 is not comparable with revenue from operations of the corresponding quarter of the previous year and nine months ended 31 December 2016 as these periods include amount of excise duty which is not included for the quarter ended 31 December 2017 after implementation of Goods and Service Tax.

By Order of the Board  
For Neuland Laboratories Limited

Sd/-